According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected ...

Since ChatGPT came out three years ago, there has been no shortage of tech companies whose businesses some see as potential ...

We remember not only the visionary businessman and leader, but above all the great person who always sought to positively ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals ...

A sandwich board outside Cocina Madrigal, a popular, award-winning Mexican restaurant in south Phoenix, advertises that the restaurant is open. But its arrow points not into the home-turned-eatery ...

New York Mets infielder Nick Madrigal could miss the entire 2025 season with a fractured left shoulder. Manager Carlos Mendoza told reporters Friday that Madrigal needs surgery to repair his ...